Upgrade to SI Premium - Free Trial

Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird

August 25, 2016 7:09 AM
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View FDA

Next Articles